Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 October 2008, Vol. 112, No. 7, pp. 2657-2666.
Prepublished online as a Blood First Edition Paper on July 7, 2008; DOI 10.1182/blood-2008-03-144634.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Tables
Right arrow All Versions of this Article:
blood-2008-03-144634v1
112/7/2657    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kisand, K.
Right arrow Articles by Peterson, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kisand, K.
Right arrow Articles by Peterson, P.
Related Collections
Right arrow Immunobiology
Right arrow Chemokines, Cytokines, and Interleukins
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

CHEMOKINES, CYTOKINES, AND INTERLEUKINS

Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes

Kai Kisand1, Maire Link1, Anette S. B. Wolff2, Anthony Meager3, Liina Tserel1, Tõnis Org1, Astrid Murumägi4, Raivo Uibo1, Nick Willcox5, Katarina Trebusak Podkrajsek6, Tadej Battelino6,7, Anna Lobell8, Olle Kämpe8, Kari Lima9, Antonella Meloni10, Berrin Ergun-Longmire11, Noel K. Maclaren12, Jaakko Perheentupa13, Kai J. E. Krohn14, Hamish S. Scott15,16, Eystein S. Husebye2,17, and Pärt Peterson1

1 Institute of General and Molecular Pathology, University of Tartu, Tartu, Estonia; 2 Institute of Medicine, University of Bergen, Bergen, Norway; 3 Biotherapeutics, National Institute for Biological Standards and Control, Potters Bar, United Kingdom; 4 Institute of Medical Technology, University of Tampere, Tampere, Finland; 5 Neurosciences Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom; 6 Centre for Medical Genetics and 7 Department of Pediatric Endocrinology, Diabetes and Metabolism, University Children's Hospital, Ljubljana, Slovenia; 8 Department of Medical Sciences, Uppsala University, Uppsala, Sweden; 9 Section of Endocrinology, Akershus University Hospital, University of Oslo, Oslo, Norway; 10 Pediatric Clinic II, Ospedale Microcitemico and Department of Biomedical and Biotechnological Science, University of Cagliari, Sardinia, Italy; 11 Division of Pediatric Endocrionology, UMDNJ/Robert Wood Johnson Medical School, New Brunswick, NJ; 12 Bioseek Clinics, New York, NY; 13 Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland; 14 Dermagene Oy, Tampere, Finland; 15 Division of Molecular Medicine, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia; 16 Division of Molecular Pathology, Institute of Medical and Veterinary Science and the Hanson Institute, School of Medicine at the University of Adelaide, Adelaide, Australia; and 17 Department of Medicine, Haukeland University Hospital, Bergen, Norway

Neutralizing autoantibodies to type I, but not type II, interferons (IFNs) are found at high titers in almost every patient with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED), a disease caused by AIRE gene mutations that lead to defects in thymic T-cell selection. Combining genome-wide expression array with real time RT-PCR assays, we here demonstrate that antibodies against IFN-{alpha} cause highly significant down-regulation of interferon-stimulated gene expression in cells from APECED patients' blood by blocking their highly dilute endogenous IFNs. This down-regulation was lost progressively as these APECED cells matured in cultures without neutralizing autoantibodies. Most interestingly, a rare APECED patient with autoantibodies to IFN-{omega} but not IFN-{alpha} showed a marked increase in expression of the same interferon-stimulated genes. We also report unexpected increases in serum CXCL10 levels in APECED. Our results argue that the breakdown of tolerance to IFNs in AIRE deficiency is associated with impaired responses to them in thymus, and highlight APECED as another autoimmune disease with associated dysregulation of IFN activity.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020